Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2025

Genmab — November 2025

Planlagt Fastgjort Låst Flyttet Genmab
176 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Plimsoller
    wrote on sidst redigeret af
    #15

    Thank you 🙂

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #16

      😉

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #17

        the FDA reversed its previous position on a sBLA for UniQure and the stock drops 56%. not sure if that is what drives biotech sentiment this US morning but not a good bio-start for november...

        1 Reply Last reply
        0
        • L Offline
          L Offline
          lahn1
          wrote on sidst redigeret af
          #18

          Er det bare mig eller bliver real world data på Epco og Glofi udlagt negativt. Man kan jo ikke sammenligne trials hvor pts skal være CD20 +ve med real world data i 3L hvor 80% af pts har tabt CD20 expression. Nogen som har et bud på om dette vil ændre peak sales på Epco ? Søg på Epcoritamab på X og jeg syntes budskabet er epco/Glofi præsterer dårligere i real life end i trials.

          1 Reply Last reply
          0
          • N Offline
            N Offline
            npo
            wrote on sidst redigeret af
            #19

            My two cents : Whereas writer – and I trust other investors - appreciate in-put with a technical background from professionals in this forum. Regrettably, however, due to use of acronyms and abbreviations in-put often becomes so technical it often comes across gobbledygook – incomprehensible to ordinary mortals (investors). Use of “simpler” terms and less acronyms etc. could enable/attract more investors to read and follow progress and in the process be attracted to support Genmab.

            1 Reply Last reply
            0
            • B Offline
              B Offline
              Bella1
              wrote on sidst redigeret af
              #20

              Tak, npo

              1 Reply Last reply
              0
              • SEACOPS Offline
                SEACOPS Offline
                SEACOP
                wrote on sidst redigeret af
                #21

                Jeg nyder det høje niveau i dette forum, hvor jeg lærer meget. Det, som jeg ikke forstår, springer jeg nemt over. For mig findes kun dette sted, hvis jeg vil have god indsigt. Fortsæt venligst. Tak.

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #22

                  Det koster blod, sved og tåre at være investeret i biotech. Jeg har sprugt meget i flere år 🙂 Skriv en liste på alle de forkortelser og akronymer du har mødt, så er jeg sikker på de profesionelle her på PI er villige til at forklare. Det er min erfaring.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #23

                    Pfizer Q3 2025 Tivdak $37mn , YTD $115mn . Now i don't know if this is the full number, as somewhere this year Genmab would assume more responsibilities for Tivdak / leading commercialization in Europe , so not sure who books what at the moment...

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #24

                      Knock-Your-Socks-Off-News – November 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-november-2025-genmab-vy0ze/

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #25

                        TEPEZZA
                        ® (teprotumumab-trbw) sales increased 15% year-over-year to $560 million in the third quarter, driven by higher inventory levels and higher net selling price https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2025-financial-results

                        1 Reply Last reply
                        0
                        • L Offline
                          L Offline
                          lahn1
                          wrote on sidst redigeret af
                          #26

                          Har ikke noteret mig salget fra jnj og de øvrige partnere helt næøjagtigt, men vi ligger vel til en opjustering

                          1 Reply Last reply
                          0
                          • R Offline
                            R Offline
                            Raun
                            wrote on sidst redigeret af
                            #27

                            Schyyyyy.... Opjusteringer er noget være lort for kursen

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #28

                              Ser ud til at markedet regner med en solid opjustering. Aktien falder 2,4% pt.

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gdn55
                                wrote on sidst redigeret af
                                #29

                                Novo nede med ca. 3,5 Ambu 18 Zeeland 3,5 Genmab 2,5.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #30

                                  Genmab A/S is set to announce its Q3 2025 earnings on November 6, 2025, with analysts expecting earnings of $0.47 per share and revenue of $975.4 million https://www.marketbeat.com/instant-alerts/genmab-as-gmab-expected-to-announce-quarterly-earnings-on-thursday-2025-10-30/

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #31

                                    Genmab AS (GMAB, Financial) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $986.99 million, and the earnings are expected to come in at $0.46 per share. https://www.gurufocus.com/news/3185679/genmab-as-gmab-q3-2025-earnings-report-preview-what-to-look-for

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #32

                                      seekingalpha: Genmab (GMAB) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. The consensus EPS Estimate is $0.45 and the consensus revenue estimate is $983.65M.

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        Pensionisten
                                        wrote on sidst redigeret af
                                        #33

                                        Regnskab vel først efter markedet i DK er lukket - oplyst efter kl. 17.00 - som sædvanligt.

                                        1 Reply Last reply
                                        0
                                        • R Offline
                                          R Offline
                                          Raun
                                          wrote on sidst redigeret af
                                          #34

                                          Flot dag i US - et luk lige i underkanten af 1900 under pæn omsætning

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper